Sign In
Buy RDHL
$1.00
-0.0100 (-0.99%)
At Close: Jun 03, 2026
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively d
Bessor Announces Entering Option for the Redhill Property
11:23am, Tuesday, 26'th May 2026
Vancouver, BC, May 26, 2026 (GLOBE NEWSWIRE) -- Bessor Minerals Inc. (TSXV:BST) ("Bessor" or the “Corporation”) announces that, on February 9, 2026, it entered into an agreement (the “Agreement�
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
08:00am, Monday, 27'th Apr 2026
2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partne
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential add-on thera
Analyzing Redhill Biopharma (NASDAQ:RDHL) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)
01:24am, Monday, 06'th Apr 2026
Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both medical companies, but which is the superior investment? We
Redhill Biopharma (NASDAQ:RDHL) Share Price Crosses Below 200-Day Moving Average – What’s Next?
02:57am, Wednesday, 25'th Mar 2026
Redhill Biopharma Ltd. (NASDAQ: RDHL - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.27 and traded as
Joint U.S. Commercialization of RedHill's Talicia® Commences
07:00am, Wednesday, 25'th Feb 2026
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and
Redhill Biopharma (NASDAQ:RDHL) Share Price Passes Below 200-Day Moving Average – What’s Next?
04:33am, Thursday, 05'th Feb 2026
Redhill Biopharma Ltd. (NASDAQ: RDHL - Get Free Report) shares crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $1.39 and
What's Going On With Redhill Biopharma Stock On Tuesday?
10:26am, Tuesday, 06'th Jan 2026
Redhill Biopharma Ltd (NASDAQ: RDHL) stock is trading lower on Tuesday, possibly on profit-taking after the stock rallied roughly 36% on Monday, as per data from Benzinga Pro.
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
07:00am, Monday, 05'th Jan 2026
RHB-102 1 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
07:00am, Monday, 15'th Dec 2025
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, with leuk
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
07:00am, Monday, 01'st Dec 2025
TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
09:30am, Tuesday, 04'th Nov 2025
RALEIGH, N.C. and TEL-AVIV, Israel , Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.
Critical Review: Redhill Biopharma (NASDAQ:RDHL) and Indaptus Therapeutics (NASDAQ:INDP)
01:53am, Sunday, 26'th Oct 2025
Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Indaptus Therapeutics (NASDAQ: INDP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare th
